EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 3.0

Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer

Hye Won Lee, Eui Hyun Jung, Kyung Hwan Kim, Hong Koo Ha, Jong Jin Oh, Seok Ho Kang, Seung-Hwan Jeong, Hyeong Dong Yuk, Ji Eun Heo, Won Sik Ham, Eu Chang Hwang, Seung Il Jung und 5 weitere

Cancer Research and Treatment · 15.04.2026 · 58 (2) · 591-602

DOI: 10.4143/crt.2025.100 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2026. Verfasst von Hye Won Lee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Deoxycytidine, BCG Vaccine, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeThis study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC).Materials and MethodsThis retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models.ResultsPatients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course.ConclusionOur research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDeoxycytidineBCG VaccineAntimetabolites, AntineoplasticHumansGemcitabineMaleFemaleAgedRetrospective StudiesAdministration, IntravesicalMiddle AgedAged, 80 and overTreatment OutcomeNeoplasm Recurrence, LocalCystectomyNeoplasm InvasivenessAdultNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Bacillus Calmette–GuérinFailureGemcitabineIntravesical administrationNon-muscle invasive bladder neoplasmsOrganization and administrationTherapeutics

Substanzen

GemcitabineDeoxycytidineBCG VaccineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea.
  • Department of Urology, Pusan National University Hospital, Pusan National University College of Medicine, Busan, Korea.
  • Department of Urology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Förderung

  • National Cancer Center

Zitieren

APA

Lee, H. W., Jung, E. H., Kim, K. H., Ha, H. K., Oh, J. J., Kang, S. H., Jeong, S. H., Yuk, H. D., Heo, J. E., Ham, W. S., Hwang, E. C., Jung, S. I., Song, W., Lim, B., Hong, B., Jeong, B. C., & Seo, H. K. (2026). Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer. Cancer Research and Treatment, 58(2), 591-602. https://doi.org/10.4143/crt.2025.100

Vancouver

Lee HW, Jung EH, Kim KH, Ha HK, Oh JJ, Kang SH, et al. Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer. Cancer Research and Treatment. 2026;58(2):591-602. doi:10.4143/crt.2025.100

BibTeX
@article{Lee2026,
  author = {Lee, Hye Won and Jung, Eui Hyun and Kim, Kyung Hwan and Ha, Hong Koo and Oh, Jong Jin and Kang, Seok Ho and Jeong, Seung-Hwan and Yuk, Hyeong Dong and Heo, Ji Eun and Ham, Won Sik and Hwang, Eu Chang and Jung, Seung Il and Song, Wan and Lim, Bumjin and Hong, Bumsik and Jeong, Byung Chang and Seo, Ho Kyung},
  title = {Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer},
  journal = {Cancer Research and Treatment},
  year = {2026},
  volume = {58},
  number = {2},
  pages = {591--602},
  doi = {10.4143/crt.2025.100}
}
Kostenlos starten →